Noile-Immune Biotech Inc. (TYO:4893)
Japan
· Delayed Price · Currency is JPY 142.00
-3.00 (-2.07%)
Apr 28, 2025, 3:30 PM JST
Noile-Immune Biotech Revenue
In the year 2024, Noile-Immune Biotech had annual revenue of 7.00M JPY, down -97.78%. Noile-Immune Biotech had revenue of 2.00M in the quarter ending December 31, 2024.
Revenue
7.00M
Revenue Growth
-97.78%
P/S Ratio
878.41
Revenue / Employee
280.00K
Employees
25
Market Cap
6.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.00M | -309.00M | -97.78% |
| Dec 31, 2023 | 316.00M | -309.00M | -49.44% |
| Dec 31, 2022 | 625.00M | 525.00M | 525.00% |
| Dec 31, 2021 | 100.00M | 3.00M | 3.09% |
| Dec 31, 2020 | 97.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Daiichi Sankyo Company | 1,886.26B |
| Takeda Pharmaceutical Company | 4,579.02B |
| HOYA Corporation | 838.60B |
| Terumo | 1,011.15B |
| Otsuka Holdings | 2,329.86B |
| Astellas Pharma | 1,912.32B |
| Olympus | 993.33B |